Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Knee Osteoarthritis
- Main trialPhase 3
- “The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.”In the company’s words, NCT04427930 on ClinicalTrials.gov
- Other names
- Autologous Adipose Tissue derived MSCs
Other drugs for Knee Osteoarthritis
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
- JointStemNature Cell Co. Ltd. · Phase 2/3
Coming up1
- 23 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 23 Dec 2026 | Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial | |
| Phase 3Completed | 15 Dec 2020 | A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis | |
| Phase 2Completed | 9 Dec 2020 | Follow-up Study for Participants Jointstem Clinical Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026